top-banner

NEWS ROOM

New Study Published by Medicover Genetics Team Demonstrates the Value of Our Liquid Biopsy Test NeoThetis in Clinical Settings

Medicover Genetics is pleased to announce the successful publication of a collaborative research article in ESMO Gastrointestinal Oncology. The investigation evaluates the efficacy of anti-EGFR re-challenge strategies with the objective to improve precision treatment options for patients with metastatic colorectal cancer (CRC).

The research teams aimed to identify novel, clinically significant prognostic genetic biomarkers through translational molecular approaches. To facilitate the accurate identification of specific biomarkers, NeoThetis liquid biopsy test, among other methods, has been utilized for the analysis. The findings highlight the reliability of NeoThetis in providing actionable insights on CRC development and therapy resistance mechanisms that could potentially improve CRC patients’ clinical management and outcomes.

“Our liquid biopsy test, NeoThetis for Therapy Selection, demonstrates utility and relevance in clinical settings as evident in this important study” stated Dr. Marios Ioannidis Managing Director of Medicover Genetics, Cyprus. “This achievement resulted from the joint efforts of our R&D, Clinical Services, and esteemed external research collaborators. It underscores Medicover Genetics commitment to advancing research that yields new insights into disease mechanisms and identifies novel therapeutic avenues.”

Medicover Genetics is dedicated to delivering research excellence that directly benefits both healthcare providers and patients.

About NeoThetis liquid biopsy

NeoThetis is part of the NeoSentia liquid biopsy portfolio that identifies genetic alterations and genomic biomarkers in a patients’ tumor. It is specifically designed to maximize the available therapeutic opportunities which are based on precision medicine while guiding therapy selection and treatment re-evaluation tailored to each patient.

OUR NETWORK